830 WINTER STREET, WALTHAM, MA
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Annual Report to Security Holders
Q32 Bio Inc. Enters Controlled Equity Offering Sales Agreement for $14.2M
Financial Results, Press Release
Announces $10.5 Million Registered Direct Offering
Mark Iwicki Withdraws Resignation from Q32 Bio Board of Directors
Sells Complement Inhibitor ADX-097
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence
Post-Effective Amendment to Registration Statement